Leukemia Clinical Trials in Houston

Showing 301-320 of 1,435 trials

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

NCT05001828

Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.

Acute Myeloid Leukemia, Adult

Polaris Group38 participantsStarted Apr 2022

Miami, Florida, United States • Charlotte, North Carolina, United States • Houston, Texas, United States

RECRUITINGPhase 1/2< 1 mile

A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

Memorial Sloan Kettering Cancer Center52 participantsStarted Jan 2026

Duarte, California, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +7 more locations

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

A Study of Revumenib and Mezigdomide in People With Leukemia

Leukemia Trials in Other Cities

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Adoption of Audio Recording in the Outpatient Supportive Care Center

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

A Study of DM005 in Patients With Advanced Solid Tumors

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Other Conditions in Houston